HRP20000079A2 - Heterocyclic vinylethers against neurological disorders - Google Patents
Heterocyclic vinylethers against neurological disorders Download PDFInfo
- Publication number
- HRP20000079A2 HRP20000079A2 HR20000079A HRP20000079A HRP20000079A2 HR P20000079 A2 HRP20000079 A2 HR P20000079A2 HR 20000079 A HR20000079 A HR 20000079A HR P20000079 A HRP20000079 A HR P20000079A HR P20000079 A2 HRP20000079 A2 HR P20000079A2
- Authority
- HR
- Croatia
- Prior art keywords
- vinyl
- compounds
- phenyl
- triazole
- dichlorophenyl
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title claims description 6
- 208000025966 Neurological disease Diseases 0.000 title claims description 6
- -1 Heterocyclic vinylethers Chemical class 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- WTPIKODEIQEHHW-UHFFFAOYSA-N 1-[2-butoxy-2-(4-chlorophenyl)ethenyl]-1,2,4-triazole Chemical compound C=1C=C(Cl)C=CC=1C(OCCCC)=CN1C=NC=N1 WTPIKODEIQEHHW-UHFFFAOYSA-N 0.000 claims description 6
- SKAYRDVTMVVMKL-UHFFFAOYSA-N 1-[2-cyclohexyloxy-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole Chemical compound ClC1=CC(Cl)=CC=C1C(OC1CCCCC1)=CN1N=CN=C1 SKAYRDVTMVVMKL-UHFFFAOYSA-N 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 150000002367 halogens Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- ABVXVPZILYLGMQ-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-phenylmethoxyethenyl]tetrazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC=CC=1)=CN1N=NN=C1 ABVXVPZILYLGMQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- OYEKXPUKWPBDPH-UHFFFAOYSA-N 1-[2-butoxy-2-(2,6-dichlorophenyl)ethenyl]-1,2,4-triazole Chemical compound ClC=1C=CC=C(Cl)C=1C(OCCCC)=CN1C=NC=N1 OYEKXPUKWPBDPH-UHFFFAOYSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- KUVSMUPNINYCGZ-UHFFFAOYSA-N 2-[2-butoxy-2-(4-chlorophenyl)ethenyl]tetrazole Chemical compound C=1C=C(Cl)C=CC=1C(OCCCC)=CN1N=CN=N1 KUVSMUPNINYCGZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000000203 mixture Substances 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 9
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OLNGHNMEXQKLJP-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-2-(tetrazol-2-yl)ethanone Chemical compound ClC1=CC(Cl)=CC=C1C(=O)CN1N=NC=N1 OLNGHNMEXQKLJP-UHFFFAOYSA-N 0.000 description 7
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- XOHMICFWUQPTNP-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-yl)ethanone Chemical compound ClC1=CC(Cl)=CC=C1C(=O)CN1N=CN=C1 XOHMICFWUQPTNP-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 6
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- YFYNOWXBIBKGHB-FFWSUHOLSA-N (1s,3s)-1-aminocyclopentane-1,3-dicarboxylic acid Chemical compound OC(=O)[C@]1(N)CC[C@H](C(O)=O)C1 YFYNOWXBIBKGHB-FFWSUHOLSA-N 0.000 description 4
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- ROKJHWJMTXQYJD-UHFFFAOYSA-N 1-[1-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-yl)ethenyl]cyclopropane-1-carboxylic acid Chemical compound C1=NC=NN1C=C(C=1C(=CC(Cl)=CC=1)Cl)C1(C(=O)O)CC1 ROKJHWJMTXQYJD-UHFFFAOYSA-N 0.000 description 3
- IPJOWHRNDGGEAE-UHFFFAOYSA-N 1-[2-(4-methylphenyl)-2-propan-2-yloxyethenyl]-1,2,4-triazole Chemical compound C=1C=C(C)C=CC=1C(OC(C)C)=CN1C=NC=N1 IPJOWHRNDGGEAE-UHFFFAOYSA-N 0.000 description 3
- WSOAIAJKFKYATC-UHFFFAOYSA-N 1-[2-butoxy-2-(2,4-dichlorophenyl)ethenyl]imidazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(OCCCC)=CN1C=CN=C1 WSOAIAJKFKYATC-UHFFFAOYSA-N 0.000 description 3
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 3
- VYWPPRLJNVHPEU-UHFFFAOYSA-N 2-chloro-1-(2,4-dichlorophenyl)ethanone Chemical compound ClCC(=O)C1=CC=C(Cl)C=C1Cl VYWPPRLJNVHPEU-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
- SOUVGVXCDDQYCI-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-phenylmethoxyethenyl]-1,2,4-triazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC=CC=1)=CN1N=CN=C1 SOUVGVXCDDQYCI-UHFFFAOYSA-N 0.000 description 2
- HVPOYWGCWYAXMX-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-propan-2-yloxyethenyl]imidazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(OC(C)C)=CN1C=CN=C1 HVPOYWGCWYAXMX-UHFFFAOYSA-N 0.000 description 2
- RUPAZAIKPULYKU-UHFFFAOYSA-N 1-[2-(2,6-dichlorophenyl)-2-phenylmethoxyethenyl]-1,2,4-triazole Chemical compound ClC1=CC=CC(Cl)=C1C(OCC=1C=CC=CC=1)=CN1N=CN=C1 RUPAZAIKPULYKU-UHFFFAOYSA-N 0.000 description 2
- AQFXIWDRLHRFIC-UHFFFAOYSA-N 1-[5-phenyl-3-(trifluoromethyl)pyrazol-1-yl]ethanone Chemical compound CC(=O)N1N=C(C(F)(F)F)C=C1C1=CC=CC=C1 AQFXIWDRLHRFIC-UHFFFAOYSA-N 0.000 description 2
- PWSQTUCTQFOJKU-UHFFFAOYSA-N 2-[2-(2,4-dichlorophenyl)-2-[(4-methoxyphenyl)methoxy]ethenyl]tetrazole Chemical compound C1=CC(OC)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)=CN1N=NC=N1 PWSQTUCTQFOJKU-UHFFFAOYSA-N 0.000 description 2
- MQHOMRXROQFFSU-UHFFFAOYSA-N 2-[2-(2,4-dichlorophenyl)-2-propan-2-yloxyethenyl]tetrazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(OC(C)C)=CN1N=CN=N1 MQHOMRXROQFFSU-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- VEZNCHDBSQWUHQ-UHFFFAOYSA-N chlorocyclopropane Chemical compound ClC1CC1 VEZNCHDBSQWUHQ-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- VHLRUGZSAQKKLU-UHFFFAOYSA-N cyclohexyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC1CCCCC1 VHLRUGZSAQKKLU-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- NDJBHBQUEAGIOB-UHFFFAOYSA-N propan-2-yl trifluoromethanesulfonate Chemical compound CC(C)OS(=O)(=O)C(F)(F)F NDJBHBQUEAGIOB-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RGYIISVBVGLAPZ-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-2-(1,2,4-triazol-1-yl)ethanone Chemical compound ClC1=CC=CC(Cl)=C1C(=O)CN1N=CN=C1 RGYIISVBVGLAPZ-UHFFFAOYSA-N 0.000 description 1
- FMECXELZNVDTPS-UHFFFAOYSA-N 1-(2-phenyl-2-propan-2-yloxyethenyl)-1,2,4-triazole Chemical compound C=1C=CC=CC=1C(OC(C)C)=CN1C=NC=N1 FMECXELZNVDTPS-UHFFFAOYSA-N 0.000 description 1
- ZFWAVFITNQYLMB-UHFFFAOYSA-N 1-(4-methylphenyl)-2-(1,2,4-triazol-1-yl)ethanone Chemical compound C1=CC(C)=CC=C1C(=O)CN1N=CN=C1 ZFWAVFITNQYLMB-UHFFFAOYSA-N 0.000 description 1
- YASHINYHANEEFV-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-(2-methylpropoxy)ethenyl]-1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(OCC(C)C)=CN1C=NC=N1 YASHINYHANEEFV-UHFFFAOYSA-N 0.000 description 1
- QQTYGKIZIDPGRU-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-methoxyethenyl]-1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(OC)=CN1C=NC=N1 QQTYGKIZIDPGRU-UHFFFAOYSA-N 0.000 description 1
- AZGZZCSYRASLDM-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-propan-2-yloxyethenyl]-1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(OC(C)C)=CN1C=NC=N1 AZGZZCSYRASLDM-UHFFFAOYSA-N 0.000 description 1
- KWUUCSRHZCDZDO-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-propan-2-yloxyethenyl]tetrazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(OC(C)C)=CN1C=NN=N1 KWUUCSRHZCDZDO-UHFFFAOYSA-N 0.000 description 1
- WMEPIKCVGRXWLS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)ethenyl]-2-phenylmethoxy-3H-1,2,4-triazole Chemical compound ClC1=C(C=CC(=C1)Cl)C=CN1N(CN=C1)OCC1=CC=CC=C1 WMEPIKCVGRXWLS-UHFFFAOYSA-N 0.000 description 1
- DOPSRBWGGYPQNB-UHFFFAOYSA-N 1-[2-(2,4-difluorophenyl)-2-propan-2-yloxyethenyl]-1,2,4-triazole Chemical compound C=1C=C(F)C=C(F)C=1C(OC(C)C)=CN1C=NC=N1 DOPSRBWGGYPQNB-UHFFFAOYSA-N 0.000 description 1
- GOXGOXAFQGUKBA-UHFFFAOYSA-N 1-[2-(4-bromophenyl)-2-butoxyethenyl]-1,2,4-triazole Chemical compound C=1C=C(Br)C=CC=1C(OCCCC)=CN1C=NC=N1 GOXGOXAFQGUKBA-UHFFFAOYSA-N 0.000 description 1
- KXUBKOIRGILENJ-UHFFFAOYSA-N 1-[2-(4-fluorophenyl)-2-propan-2-yloxyethenyl]-1,2,4-triazole Chemical compound C=1C=C(F)C=CC=1C(OC(C)C)=CN1C=NC=N1 KXUBKOIRGILENJ-UHFFFAOYSA-N 0.000 description 1
- XLJAVQLWVBPOAU-UHFFFAOYSA-N 1-[2-propan-2-yloxy-2-(2,4,6-trichlorophenyl)ethenyl]-1,2,4-triazole Chemical compound ClC=1C=C(Cl)C=C(Cl)C=1C(OC(C)C)=CN1C=NC=N1 XLJAVQLWVBPOAU-UHFFFAOYSA-N 0.000 description 1
- AWNXKZVIZARMME-UHFFFAOYSA-N 1-[[5-[2-[(2-chloropyridin-4-yl)amino]pyrimidin-4-yl]-4-(cyclopropylmethyl)pyrimidin-2-yl]amino]-2-methylpropan-2-ol Chemical compound N=1C(NCC(C)(O)C)=NC=C(C=2N=C(NC=3C=C(Cl)N=CC=3)N=CC=2)C=1CC1CC1 AWNXKZVIZARMME-UHFFFAOYSA-N 0.000 description 1
- FNOGEZGAOZSVPP-UHFFFAOYSA-N 2-[2-butoxy-2-(2,4-dichlorophenyl)ethenyl]tetrazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(OCCCC)=CN1N=CN=N1 FNOGEZGAOZSVPP-UHFFFAOYSA-N 0.000 description 1
- TVBKZSJFNJEZNI-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-4-(1,2,4-triazol-1-yl)but-3-enoic acid Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(CC(=O)O)=CN1C=NC=N1 TVBKZSJFNJEZNI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 1
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 description 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 1
- 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 description 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 1
- 102100038300 Metabotropic glutamate receptor 6 Human genes 0.000 description 1
- 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 101001071458 Rattus norvegicus Metabotropic glutamate receptor 2 Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FGNLEIGUMSBZQP-UHFFFAOYSA-N cadaverine dihydrochloride Chemical compound Cl.Cl.NCCCCCN FGNLEIGUMSBZQP-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003823 glutamate receptor agonist Substances 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 1
- 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 1
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 description 1
- 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 description 1
- 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 description 1
- 108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Predloženi izum odnosi se na heterocikličke vinil etere opće formule
[image]
u kojoj
R predstavlja halogen ili niži alkil;
n je 0 do 3;
R1 je niži alkil; cikloalkil; benzil proizvoljno supstituiran s hidroksi, halogenim, nižim alkoksi ili nižim alkilom; benzoil proizvoljno supstituiran s amino, nižim alkilamino ili di-nižim alkilamino; acetil ili cikloalkil-karbonil; i
(A) predstavlja aromatski peteročlani ostatak koji je povezan preko dušikovog atoma i koji, osim veznog N atoma, sadrži još 1-3 N atoma,
kao i na njihove farmaceutski prihvatljive soli za liječenje ili prevenciju bolesti.
Neki derivati triazola, koji spadaju medu spojeve formule I, poznati su već dugo vremena. Oni su opisani npr. u Europskoj patentnoj prijavi br. 079 856, kao aktivne tvari koje se upotrebljavaju pri agrokemijskom suzbijanje štetočina, posebno za suzbijanje ili sprečavanje napada mikroorganizama.
Iznenađujuće je pronađeno da su spojevi opće formule 1 antagonisti i/ili agonisti metabotropnog glutamat receptora.
U središnjem živčanom sistemu (CNS) transmisija podražaja odvija se interakcijom neutrotransmitera, koja se odašilje pomoću neurona, s neurorecptorom.
L-glutaminska kiselina, neurotransmiter koji najčešće nastaje u CNS-u, ima kritičnu ulogu u velikom broju fizioloških procesa. O glutamatu ovisni receptori podražaja podijeljeni su u dvije glavne skupine. Prva glavna skupina tvori ligandima kontrolirane ionske kanale. Metabotropni glutamat receptori (mGluR) spadaju u drugu skupinu i, nadalje, oni spadaju u porodicu receptora povezanih s G-proteinom.
Za sada je poznato osam različitih članova tih mGluR-a i neki od njih imaju čak i pod-tipove. Na osnovi strukturnih parametara, različitih utjecaja na sintezu sekundarnih metabolita i različitog afiniteta prema kemijskim spojevima niske molekulske mase, tih osam receptora mogu se podijeliti na tri podskupine:
mGluR1 i mGluR5 spadaju u skupinu I, mGluR2 i mGluR3 spadaju u skupinu II, a mGluR4, mGluR6, mGluR7 i mGluRS spadaju u skupinu III.
Ligandi metabotropnih glutamat receptora, koji spadaju u drugu skupinu, mogu se upotrijebiti za liječenje ili za prevenciju akutnih i/ili kroničnih neuroloških poremećaja kao što je ograničena funkcija mozga uzrokovana operacijama premoštenja ili presađivanja, slabim dovođenjem krvi u mozak, povredom spinalnog korda, hipoksijom uzrokovanom trudnoćom, kardijalnim arestom i hipoglikemijom.
Druge indikacije koje se mogu liječiti s tim u svezi jesu Alzheimerova bolest, Huntingtonova bolest, amiotrofna lateralna skleroza (ALS), demencija uzrokovana AIDS-om, povrede očiju, retinopatija, spoznajni poremećaji, idiopatski parkinsonizam ili parkinsonizam uzrokovan lijekovima, kao i stanja koja dovode do glutamatne deficijencije funkcija kao što su npr. mišićne spazme, konvulzije, migrena, urinarna inkontinencija, odvikavanje od nikotina, psihoze, odvikavanje od opijata, anksioznost, povraćanje, kronični bol, diskinezija, depresije i bolovi.
Predmet predloženog izuma je upotreba spojeva formule I i njihovih farmaceutski prihvatjivih soli kao terapeutski aktivnih tvari, kao i lijekova na osnovi ovih spojeva, te njihova proizvodnja, i novi spojevi formule I i njihove farmaceutski prihvatljive soli kao takove i kao farmaceutski aktivne tvari za suzbijanje ili prevenciju bolesti gore spomenute vrste.
Novi spojevi formule I jesu posebno oni u kojima R i R1 imaju gore data značenja, a A je aromatski peteročlani prsten koji je povezan preko dušikovog atoma i koji osim veznog N atoma sadrži još 1 do 3 dušikova atoma, ili u kojoj R ima gore dato značenje, A je aromatski peteročlani prsten koji je povezan preko N atoma i koji osim veznog N atoma sadrži još 1 do 3 N atoma, i R1 je cikloalkil.
Pojam “niži alkil”, upotrijebljen u predloženom opisu, označava zasićen ugljikovodični ostatak ravnog ili razgranatog lanca koji ima od 1 do 7 ugljikovih atoma, ponajprije od 1 do 4 ugljikova atoma, kao metil, etil, n-propil i slično.
Pojam “cikloalkil” označava ciklički zasićen ugljikovodični ostatak koji ima od 3 do 7 ugljikovih atoma u prstenu, kao na primjer ciklopropil, ciklobutil, ciklopentil, cikloheksil i slično.
Pojam “niži alkoksi” označava niži alkilni ostatak, u smislu prethodne definicije, koji je povezan preko atoma kisika.
Pojam “halogen” obuhvaća fluor, klor, brom i jod.
U smislu predloženog izuma spojevi opće formule I, u kojoj R označava klor, n je 1 ili 2, R1 je niži alkil, cikloheksil ili benzil, i A je aromatski peteročlani prsten koji je povezan preko N atoma i koji osim veznog N atoma sadrži još 2 ili 3 dodatna N atoma, prednosni su za upotrebu kao terapeutski aktivne tvari.
Primjeri prednosnih spojeva formule I su slijedeći spojevi:
1-[2- (2, 4-diklorfenil) -2-cikloheksiloksi-vinil]-1H-[1,2,4]triazol,
1-[2- (2, 4-diklorfenil) -2-benziloksi-vinil]-1H-tetrazol,
2-[2- (4-klorfenil) -2-butoksi-vinil]-2H-tetrazol,
1-[2- (4-klorfenil) -2-butoksi-vinil]-1H-[1,2,4]triazol i
1-[2- (2, 6-diklorfenil) -2-butoksi-vinil]-1H-[1,2,4]-triazol.
Novi spojevi opće formule I mogu se proizvesti prema izumu alkiliranjem ili aciliranjem spoja formule
[image]
u kojoj R, n i A imaju ranije data značenja, i po želji, pretvorbom dobivenog spoja formule I u njegovu farmaceutski prihvatljivu sol.
Po želji, funkcionalna skupina u spoju formule I može se prevesti u drugu funcionalnu skupinu; posebno, amino skupine mogu se alkilirati u niže alkilamino ili di-niže alkilamino skupine, ili se hidroksi skupine mogu alkilirati. Ti postupci su poznati svakom stručnjaku.
Kod alkiliranja ili aciliranja acetofenonski derivat formule II reagira s prikladnim sredstvom za alkiliranje ili aciliranje, prednosno s benzil bromidom, benzoil kloridom, acetil kloridom, cikloheksil triflatom, ciklopropil kloridom, izopropil bromidom, n-butil bromidom, n-butil bromid, 4-metoksibenzil klorid, izopropil triflatom, 4-dimetilaminobenzoil kloridom, benzil kloridom i slično. Ta se reakcija provodi u skladu s poznatim metodama, ponajprije u prisutnosti natrijevog hidrida. Kao otapalo posebno je prikladna mješavina THF (tetrahidrofuran) i DMPU (1, 3-dimetil-3, 4, 5, 6-tetrahidro-2(1H)-pirimidinon) u omjeru 3:1.
Inačica proizvodnje opisana je pojedinostima u primjeru Ib).
Farmaceutski upotrebljive soli mogu se proizvesti lako u skladu s poznatim metodama, imajući u vidu prirodu spoja koji se želi prevesti u sol. Za tvorbu farmaceutski upotrebljivih soli bazičnih spojeva formule I prikladne su anorganske kiseline, kao na primjer solna kiselina, bromovodična kiselina, sumporna kiselina, dušična kiselina, fosforna kiselina ili limunska kiselina, mravlja kiselina, fumarna kiselina, maleinska kiselina, octena kiselina, sukcinska kiselina, vinska kiselina, metansulfonska kiselina, p-toluensulfonska kiselina i slične. Spojevi koji sadrže alkalijske ili zemno alkalijske metale, na primjer natrij, kalij, kalcij, magnezij ili slično, bazične amine ili bazične amino kiseline, prikladni su za tvorbu farmaceutski upotrebljivih soli kiselih spojeva.
Sljedeća shema 1 prikazuje pregledno proizvodnju spojeva formule I, počevši od poznatih spojeva formule III i IV.
Shema 1
[image]
U ovoj shemi R, n i A imaju gore navedena značenja, X je halogen, ponajprije klor ili brom. Spoj formule IV može biti prednosno triazol, tetrazol ili imidazol općih formula
[image]
Spojevi općih formula II, III i IV su poznati ili se mogu proizvesti u skladu s poznatim metodama.
Sljedeća tablica 1 prikazuje izbor ispitanih spojeva za upotrebu kao terapeutski aktivnih tvari u pokusu afiniteta mGluR-a (vidi str. 9):
[image]
[image]
[image]
A 1-[2- (2, 4-diklorfenil) -2-izopropoksi-vinil]-1H-[1,2,4]-triazol,
B 1-[2- (2, 4-diklorfenil) -2-izobutoksi-vinil]-1H-[1,2,4]-triazol,
C 1-[2- (4-klorfenil) -2-butoksi-vinil]-1H-[1,2,4]triazol,
D 1-[2- (2, 4, 6-triklorfenil) -2-izopropoksi-vinil]-1H-[1,2,4]triazol,
E 1-[2- (2, 4-diklorfenil) -2-metoksi-vinil]-1H-[1,2,4]-triazol,
F 1-[2- (4-bromfenil) -2-butoksi-vinil]-1H-[1,2,4]triazol,
G 1-[2- (2, 4-difluorfenil)-2-izopropoksi-vinil]-1H-[1,2,4]-triazol,
H 1-[2- (4-fluorfenil) -2-izopropoksi-vinil]-1H-[1,2,4]-triazol,
I 1-[2- (fenil) -2-izopropoksi-vinil]-1H-[1,2,4]triazol,
J 1-[2- (4-klorfenil) -2-butoksi-vinil]-1H-[1,2,4]triazol,
K 1-[2- (2, 6-diklorfenil) -2-butoksi-vinil]-1H-[1,2,4]-triazol,
L 1-[2- (2, 4-diklorfenil) -2-benziloksi-vinil]-1H-[1,2,4]-triazol,
M 1-(2, 4-diklorfenil) -2-[1,2,4]triazol-1-il-vinil-benzojeva kiselina ester,
N 1-(2, 4-diklorfenil) -2-[1,2,4]triazol-1-il-vinil-octena kiselina ester,
O 1-[2-(2, 4-diklorfenil) -2-cikloheksiloksi-vinil]-1H-[1,2,4]triazol,
P 1-(2, 4-diklorfenil) -2-[1,2,4]triazol-1-il-vinil-ciklopropan karboksilna kiselina ester,
Q 1-[2- (4-tolil) -2-izopropoksi-vinil]-1H-[1,2,4]triazol,
R 1-[2- (2, 4-diklorfenil) -2-benziloksi-vinil]-2H-tetrazol,
S 2-[2- (2, 4-diklorfenil) -2-butoksi-vinil]-2H-tetrazol,
T 2-[2- (4-klorfenil) -2-butoksi-vinil]-2H-[1,2,4]-tetrazol,
U 2-[2- (2, 4-diklorfenil) -2-izopropoksi-vinil]-2H-tetrazol,
V 2-[2- (2, 4-diklorfenil)-2-(4-metoksi-benziloksi)-vinil]-2H-tetrazol,
W 1-(2, 4-diklorfenil) -2-tetrazol-1-il-vinil-benzojeva kiselina ester,
X 1-[2- (2, 4-diklorfenil) -2-izopropoksi-vinilj-1H-tetrazol,
Y 1-(2, 4-diklorfenil) -2-tetrazol-1-il-vinil-4-dimetil-aminobenzojeva kiselina ester,
Z 1-[2- (2, 4-diklorfenil) -2-benziloksi-vinil]-1H-tetrazol,
AA 1-[2- (2, 4-diklorfenil) -2-izopropoksi-vinil]-1H-imidazol,
BB 1-[2- (2, 4-diklorfenil) -2-butoksi-vinil]-1H-imidazol.
Kako je gore spomenuto, spojevi formule I i njihove farmaceutski prihvatljive soli su metabotropni glutamat receptor antagonisti i/ili agonisti i mogu se upotrijebiti za liječenje ili prevenciju akutnih i/ili kroničnih neuroloških poremećaja.
Vezanje spojeva formule I prema izumu na skupinu II metabotopnih glutamat receptora odredeno je in vitro. Pripravci su ispitani u skladu s pokusom opisanim u nastavku.
Za određivanje afiniteta spoja prema skupini II mGluR-a primijenjen je pokus GTPγ35S. Upotrijebljene su membrane koje se ljepe na mGluR2 receptor štakora. One su bile stimulirane s 10 µM 1S, 3R-ACPD.
Date su Ki vrijednosti ispitanih spojeva. Ki vrijednost definirana je pomoću slijedeće formule
[image]
u kojoj vrijednosti IC50 predstavljaju koncentracije ispitivanih spojeva u µM kod kojih je antagonizirano 50% učinka 1S, 3R-ACPD. [L] je koncentracija 1S, 3R-ACPD i EC50 vrijednost je koncentracija 1S, 3R-ACPD u nM koja daje približno 50%-tnu stimulaciju.
Tablica 2
Aktivnost prema nGluR
[image]
Spojevi formule I i njihove farmaceutski prihvatljive soli mogu se upotrijebiti kao lijekovi, npr. u obliku farmaceutskih pripravaka. Farmaceutski pripravci se mogu dati oralno, npr. u obliku tableta, prevučenih tableta, dražeja, kapsula od tvrde i meke želatine, otopina, emulzija ili suspenzija. Međutim, aplikacija se također može izvršiti rektalno, npr. u obliku čepića, ili parenteralno, npr. u obliku injekcijskih otopine.
Pri proizvodnji farmaceutskih pripravaka, spojevi formule I i njihove farmaceutski prihvatljive soli mogu se preraditi s farmaceutski inertnim, anorganskim ili organskim nosačima. Laktoza, kukuruzni škrob ili njegovi derivati, talk, stearinska kiselina ili njene soli i slično mogu se upotrijebiti, na primjer, kao nosači za tablete, prevučene tablete, dražeje i kapsule od tvrde želatine. Prikladni nosači za kapsule od meke želatine jesu na primjer biljna ulja, voskovi, masti, polukruti i tekući polioli i slično; međutim, ovisno o prirodi aktivne tvari, u slučaju kapsula od meke želatine, nosač uopće ne mora biti potreban. Za proizvodnju otopina i sirupa prikladni nosači jesu, na primjer, voda, polioli, saharoza, invertni šećer, glukoza i slično. Pomoćne tvari kao alkoholi, polioli, glicerol, biljna ulja i slično, mogu se upotrijebiti za injekcijske otopine soli spojeva formule I topivih u vodi, ali u pravilu nisu neophodne. Prikladni nosači za čepiće jesu, na primjer, prirodna ili otvrdnuta ulja, voskovi, masti, polu-tekući ili tekući polioli i slično.
Također, farmaceutski pripravci mogu sadržavati konzervanse, stabilizatore, solubilizatore, sredstva za kvašenje, emulgatore, zaslađivače, bojila, začine, soli za namještanje osmotskog tlaka, pufere, sredstva za maskiranje ili antioksidante. Oni također mogu sadržavati i druge terapeutski korisne tvari.
Kako je ranije spomenuto, lijekovi koji sadrže spoj formule I, ili njegovu farmaceutski prihvatljivu sol i terapeutski inertnu pomoćnu tvar, također su predmet predloženog izuma, te nadalje, također i postupak za proizvodnju takovih lijekova, koji je naznačen time, da se jedan ili više spojeva formule I ili njegova farmaceutski prihvaltjiva sol i, po želji, jedna ili više drugih terapeutski korisnih tvari dovede u galenski oblik doziranja zajedno s jednim ili više terapeutski inertnih nosača.
Doziranje se može mijenjati u širokim granicama i ono se, naravno, mora prilagoditi pojedinačnim potrebama u svakom pojedinom slučaju. Općenito, učinkovita doza za oralno ili parenteralno davanje je između 0,01-20 mg/kg/dnevno, pri čemu se prednost daje doziranju od 0,1-10 mg/kg/dnevno za sve opisane indikacije. Dnevna doza za odraslog čovjeka tjelesne težine 70 kg kreće se prema tome između 0,7 i 1400 mg dnevno, prednosno između 7 i 700 mg dnevno.
Sljedeći primjeri predviđeni su kao ilustracija proizvodnje specifičnih novih spojeva s više pojedinosti.
Primjer 1
1-[2- (2, 4-diklorfenil) -vinil]-2-benziloksi-1H-[1,2,4]triazol
a) 10 g (44,8 mmolova) 2, 2', 4'-trikloracetophenona doda se kap po kap pri sobnoj temperaturi k otopini od 9,3 g (134 mmola) triazola u 50 ml dimetilformamida i miješa se 16 sati pri 80°C Reakcijsku smjesu se doda k 100 ml 2N otopine natrijevog hidroksida i ekstrahira se tri puta sa po 100 ml etil acetata. Sjedinjene organske faze se osuše preko magnezijevog sulfata i koncentriraju u vakuumu. Sirov proizvod očisti se kromatografijom na stupci silika gela (etil acetat/metanol 100:1). Dobiveno je 2,8 g (25%) 1 -(2, 4-diklorfenil) -2-[1,2,4]triazol-1-il-etanona kao žuto smeđe krute tvari.
b) 670 mg (2,62 mmola) 1-(2, 4-diklorfenil) -2-[1,2,4]-triazol-1-il-etanona u 12 ml tetrahidrofurana i 4 ml 1,3-dimetil-3, 4, 5, 6-tetrahidro-2(1H)-pirimidinona doda se k suspeziji od 171 mg (3,92 mmola) natrijevog hidrida (55% u mineralnom ulju) u 15 ml tetrahidrofurana i 5 ml 1, 3-dimetil-3, 4, 5, 6-tetrahidro-2 (1H) -pirimidinona (DMPU) i miješa se 3 sata pri sobnoj temperaturi. Zatim se doda 396 mg (5,24 mmolova) benzil bromida i smjesu se miješa daljnjih 16 sati pri sobnoj temperaturi. Tetrahidrofuran se odstrani pod vakuumom, ostatak se doda k 50 ml vode i ekstrahira tri puta sa po 50 ml dietil etera. Sjedinjene organske faze se osuše preko magnezijevog sulfata i dietil eter se odstrani u vakuumu. Sirov proizvod se očisti kromatografijom na stupcu silika gela (dietil eter/pentan 1:4). Dodatno, osim miješanih frakcija, sa C-alkiliranjem proizvoda dobiveno je i 65 mg (7%) čistog 1-[2-(2,4-diklorfenil) -2-benziloksi-vinil]-1H-[1,2,4]triazola kao bezbojnog ulja. [M+H]+ = 345,347.
Primjer 2
1-(2-(2,4-diklorfenil)-2-[1,2,4]triazol-1-vinil-benzojeva kiselina ester
Analogno primjeru 1a, b, nakon reakcije 1- (2, 4-diklor-fenil) -2-[1,2,4]triazol-1-il-etanona s benzoil kloridomm dobiven je čisti 1- (2, 4-diklorfenil) -2-[1,2,4]triazol-1-vinil-benzojeva kiselina ester. Nakon reakcije s oksalnom kiselinom dobivena je sol sastava C17H11N3O2Cl2 · C2H2O4 s talištem pri 130°C.
Primjer 3
1-(2, 4-diklorfenil)-2-[1,2,4]triazol-1-vinil-octena kiselina ester
Analogno primjeru 1a, b, nakon reakcije 1-(2,4-diklor-fenil) -2-[1,2,4]triazol-1-il-etanona s acetil kloridom dobiven je čisti 1- (2, 4-diklorfenil) -2-[1,2,4]triazol-1-vinil-octena kiselina ester kao bijela kruta tvar s talištem pri 127°C.
Primjer 4
1-[2- (2, 4-diklorfenil) -2-cikloheksiloksi-vinil]-1H-[1,2,4]-triazol
Analogno primjeru 1a, b, nakon reakcije 1- (2, 4-diklor-fenil) -2-[1,2,4]triazol-1-il-etanona s cikloheksil triflatom dobiven je 1-[2- (2, 4-diklorfenil) -2-cikloheksiloksi-vinil]-1H-[1,2,4]triazol kao bijela kruta tvar s talištem pri 84°C.
Primjer 5
1- (2, 4-diklorfenil) -2-[1,2,4]triazol-1-il-vinil-ciklopropan-karboksilna kiselina ester
Analogno primjeru 1a, b, nakon reakcije 1- (2, 4-diklor-fenil) -2-[1,2,4]triazol-1-il etanona s ciklopropil kloridom dobiven je 1- (2, 4-diklorfenil) -2-[1,2,4]triazol-1-il-vinil-ciklopropan-karboksilna kiselina ester kao bijela kruta tvar s talištem pri 108°C.
Primjer 6
1-[2-(4-tolil) -2-izopropiloksi-vinil]-1H-[1,2,4]triazol
Analogno primjeru 1a, b, nakon reakcije 1- (4-metil-fenil) -2-[1,2,4]triazol-1-il-etanona s izopropil bromidom dobiven je 1-[2- (4-tolil) -2-izopropiloksi-vinil]-1H-[l, 2, 4]-triazol. Nakon reakcije s HCl u dioksanu dobivena je sol sastava C14H17N3O · HC1. [M+H+ = 243.
Primjer 7
1-[2-(2,6-diklorfenil) -2-benziloksi-vinil]-1H-[l, 2, 4]triazol
Analogno primjeru 1a, b, nakon reakcije 1- (2, 6-diklor-fenil) -2-[1,2,4]triazol-1-il-etanona s benzil kloridom dobiven je 1-[2-(2,6-diklorfenil) -2-benziloksi-vinil]-1H-[1,2,4]triazol. Nakon reakcije s oksalnom kiselinom dobivena je sol sastava C17H13N3OCl2 · C2H2O4, koja se raspada pri >70°C.
Primjer 8
2-[2- (2, 4-diklorfenil) -2-butoksi-vinil]-1H-[1,2,4]triazol
a) Otopinu od 15,9 g (71 mmola) 2, 2', 4' -triklor-acetofenona u 100 ml metilen klorida polako se, kap po kap, i uz hlađenje s ledom doda k otopini od 4,98 g (71 mmola) tetrazola i 14,4 g (142 mmola) trietilamina u 100 ml metilen klorida i grije se 16 sati pod refluksom. Reakcijsku smjesu se doda k 100 ml vode i ekstrahira tri puta sa po 100 ml metilen klorida. Sjedinjene organske faze se osuše preko magnezijevog sulfata i koncentriraju u vakuumu. Sirov proizvod se očisti kromatografijom na stupcu silika gela (etil acetat/heksan 1:1). Dobiveno je 4,75 g (26%) 1- (2, 4-diklor) -2-tetrazol-1-il)-etanona i 7,80 g (43%) 1- (2, 4-diklorfenil) -2-tetrazol-2-il-etanona.
b) Analogno primjeru 1b, nakon reakcije 1- (2, 4-diklor-fenil) -2-tetrazol-2-il)-etanona s n-butil bromidom dobiven je 2-[2- (2, 4-diklorfenil) -2-butoksi-vinil]-1H-[l, 2, 4]triazol kao bezbojno ulje. [M+H]+ = 313.
Primjer 9
2-[2- (4-klorfenil) -2-butoksi-vinil]-2H-[1,2,4]triazol
Analogno primjeru 7a, b, nakon reakcije 1-(4-klor-fenil) -2-tetrazol-2-il)-etanona s n-butil bromidom dobiven je 2-[2- (4-klorfenil) -2-butoksi-vinil]-2H-[1,2,4]triazol kao bezbojno ulje. [M+H]+ = 279.
Primjer 10
2-[2-(2, 4-diklorfenil) -2-izopropoksi-vinil]-2H-tetrazol
Analogno primjeru 7a, b, nakon reakcije 1- (2, 4-diklor-fenil) -2-tetrazol-2-il-etanona s izopropil bromidom dobiven je 2-[2-(2,4-diklorfenil) -2-izopropoksi-vinil]-2H-tetrazol kao bezbojno ulje. [M+H]+ = 299.
Primjer 11
2-[2- (2, 4-diklorfenil) -2- (4-metoksi-benziloksi)-vinil]-2H-tetrazol
Analogno primjeru 7a, b, nakon reakcije 1- (2, 4-diklor-fenil) -2-tetrazol-2-il-etanona sa 4-metoksibenzil kloridom dobiven je 2-[2- (2, 4-diklorfenil) -2-(4-metoksi-benziloksi)-vinil]-2H-tetrazol kao bezbojno ulje. [M+H]+ = 376.
Primjer 12
1- (2, 4-diklorfenil) -2-tetrazol-1-il-vinil-benzojeva kiselina ester
Analogno primjeru 7a, b, nakon reakcije 1- (2, 4-diklor-fenil) -2-tetrazol-2-il-etanona s benzoil kloridom dobiven je 1-(2, 4-diklorfenil) -2-tetrazol-1-il-vinil-benzojeva kiselina ester kao bezbojno ulje. [M+H]+ = 360.
Primjer 13
1-[2- (2, 4-diklorfenil) -2-izopropoksi-vinil]-1H-tetrazol
Analogno primjeru 7a, b, nakon reakcije 1- (2, 4-diklor-fenil) -2-tetrazol-2-il-etanona s izopropil triflatom dobiven je 1-[2- (2, 4-diklorfenil) -2-izopropoksi-vinil]-1H-tetrazol kao bijeli prah s talištem pri 82°C.
Primjer 14
1- (2, 4-diklorfenil) -2-tetrazol-1-il-vinil) -4-dimetilamino-benzojeva kiselina ester
Analogno primjeru 7a, b, nakon reakcije 1- (2, 4-diklor-fenil) -2-tetrazol-2-il-etanona s 4-dimetilamino-benzoil kloridom dobiven je 1- (2, 4-diklorfenil) -2-tetrazol-1-il-vinil)-4-dimetilamino-benzojeva kiselina ester kao bezbojni kristali s talištem pri 135°C.
Primjer 15
1-[2- (2, 4-diklorfenil) -2-benziloksi-vinil]-1H-tetrazol
Analogno primjeru 7a, b, nakon reakcije 1- (2, 4-diklor-fenil) -2-tetrazol-2-il-etanona s benzoil kloridom dobiven je 1-[2- (2, 4-diklorfenil) -2-benziloksi-vinil]-1H-tetrazol kao bezbojni kristali s talištem pri 92°C.
Primjer 16
1-[2- (2, 4-diklorfenil) -2-izopropiloksi-vinil]-1H-imidazol
a) Analogno primjeru 1a, nakon reakcije 2, 2', 4'-trikloracetofenona s imidazolom dobiven je 1-(2,4-diklor-fenil)-2-(1H-imidazol)-1-il-etanon.
b) Analogno primjeru 1b, nakon reakcije 1- (2, 4-diklorfenil) -2-(1H-imidazol)-1-il-etanona s izopropil bromidom dobiven je 1-[2- (2, 4-diklorfenil) -2-izopropiloksi-vinil]-1H-imidazol, koji je izoliran kao sol sastava C14H14Cl2N2O HCl s talištem 184-186°C.
Primjer 17
1-[2-(2, 4-diklorfenil) -2-butoksi-vinil]-1H-imidazol
Analogno primjeru 16a, b, nakon reakcije 1- (2, 4-diklor-fenil) -2-(1H-imidazol)-1-il-etanona s n-butil bromidom dobiven je 1-[2- (2, 4-diklorfenil) -2-butoksi-vinil]-1H-imidazol, koji je izoliran kao sol sastava C15H16Cl2N2O · HC1 s talištem 205-207°C.
Primjer A
Na uobičajeni način proizvedene su tablete sljedećeg sastava:
mg/tableti
aktivan sastojak 100
praškasta laktoza 95
škrob bijelog kukuruza 35
polivinilpirolidon 8
Na karboksimetil škrob 10
magnezijev stearat 2
ukupna masa: 250
Primjer B
Na uobičajeni način proizvedene su tablete sljedećeg sastava:
mg/tableti
aktivan sastojak 200
praškasta laktoza 100
škrob bijelog kukuruza 65
polivinilpirolidon 12
Na karboksimetil škrob 20
magnezijev stearat 4
ukupna masa: 400
Primjer C
Proizvedene su kapsule sljedećeg sastava:
mg/kapsuli
aktivan sastojak 50
krist. laktoza 60
mikrokristalinična celuloza 34
talk 5
magnezijev stearat 1
ukupna masa punjenja kapsule: 150
Aktivni sastojak s prikladnom veličinom čestica, kristalinična laktoza i mikrokristalinična celuloza homogeno se pomiješaju jedno s drugim, sve se prosije i zatim se s tim pomiješa talk i magnezijev stearat. Gotovu smjesu puni se u kapsule od tvrde želatine prikladne veličine.
Claims (11)
1. Upotreba spojeva opće formule
[image]
naznačenih time, da
R predstavlja halogen ili niži alkil;
n je 0-3;
R1 je niži alkil; cikloalkil; benzil prema potrebi supstituiran s hidroksi, halogenim, nižim alkoksi ili nižim alkilom; benzoil prema potrebi supstituiran s amino, nižim alkilamino ili di-nižim alkilamino; acetil ili cikloalkil-karbonil; i
(A) predstavlja aromatski peteročlani ostatak koji je povezan preko dušikovog atoma i koji, osim veznog N atoma, sadrži još 1-3 daljnja N atoma,
te njihovih farmaceutski prihvatljivih soli za proizvodnju lijekova za suzbijanje ili prevenciju akutnih i/ili kroničnih neuroloških poremećaja.
2. Upotreba spojeva opće formule (I) prema zahtjevu 1, naznačenih time, da
R predstavlja klor;
n je 1 ili 2;
R1 je niži alkil, cikloalkil ili benzil, i
(A) predstavlja aromatski peteročlani prsten koji je povezan preko dušikovog atoma i koji, osim veznog N atoma, sadrži daljnja 2 ili 3 N atoma.
3. Upotreba spojeva 1-[2-(2,4-diklor-fenil)-2-cikloheksiloksi-vinil]-1H-[1,2,4]triazola,
1-[2-(2,4-diklor-fenil)-2-benziloksi-vinil]-1H-tetrazola,
2-[2-(4-klor-fenil)-2-butoksi-vinil]-2H-tetrazola, 1-[2-(4-klor-fenil)-2-butoksi-vinil]-lH-[1,2,4]triazola
i
1-[2-(2,6-diklor-fenil) -2-butoksi-vinil]-lH-[1,2,4]-triazola,
naznačena time, da se oni koriste u skladu sa zahtjevom 2.
4. Spojevi opće formule I, naznačeni time, da R i R1 imaju značenja data u zahtjevu 1, a (A) predstavlja aromatski peteročlani prsten koji je povezan preko dušikovog atoma i koji, osim veznog N atoma, sadrži još 3 daljnja N atoma.
5. Spojevi opće formule I, naznačeni time, da R i A imaju značenja data u zahtjevu 1, a R1 je cikloalkil.
6. Spoj 1-[2-(2,4-diklor-fenil)-2-cikloheksiloksi-vinil]-lH-[1,2,4]triazol, naznačen time, da je u skladu sa zahtjevom 5.
7. Postupak za proizvodnju spojeva prema zahtjevima 4 do 6, naznačen time, da uključuje alkiliranje ili aciliranje spoja formule
[image]
u kojoj R, n i A imaju značenja data u zahtjevu 1, i po želji, pretvorbu dobivenog spoja formule I u farmaceutski prihvatljivu sol.
8. Spojevi prema zahtjevima 4 do 6, naznačeni time, da se upotrebljavaju kao terapeutski aktivne tvari.
9. Upotreba spojeva prema zahtjevima 4 do 6, naznačena time, da se oni koriste za suzbijanje ili prevenciju bolesti, posebno za suzbijanje ili prevenciju akutnih i/ili kroničnih neuroloških poremećaja i, odnosno, za proizvodnju odgovarajućih lijekova.
10. Lijek, naznačen time, da sadrži jedan ili više spojeva prema zahtjevu 4 ili 5 i terapeutski inertnu pomoćnu tvar.
11. Lijek prema zahtjevu 10, naznačen time, da se upotrebljava za suzbijanje ili prevenciju bolesti, posebno za suzbijanje ili prevenciju akutnih i/ili kroničnih neuroloških poremećaja.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97114065 | 1997-08-14 | ||
PCT/EP1998/004890 WO1999008678A1 (en) | 1997-08-14 | 1998-08-06 | Heterocyclic vinylethers against neurological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20000079A2 true HRP20000079A2 (en) | 2000-12-31 |
Family
ID=8227219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20000079A HRP20000079A2 (en) | 1997-08-14 | 2000-02-11 | Heterocyclic vinylethers against neurological disorders |
Country Status (24)
Country | Link |
---|---|
US (2) | US6054588A (hr) |
EP (1) | EP1003505B1 (hr) |
JP (1) | JP3593031B2 (hr) |
KR (1) | KR100357650B1 (hr) |
CN (1) | CN1154489C (hr) |
AR (1) | AR016604A1 (hr) |
AT (1) | ATE262331T1 (hr) |
AU (1) | AU741532B2 (hr) |
BR (1) | BR9811933A (hr) |
CA (1) | CA2297732C (hr) |
DE (1) | DE69822638T2 (hr) |
ES (1) | ES2216305T3 (hr) |
HR (1) | HRP20000079A2 (hr) |
HU (1) | HUP0004412A3 (hr) |
ID (1) | ID28529A (hr) |
IL (1) | IL134168A0 (hr) |
NO (1) | NO20000738L (hr) |
NZ (1) | NZ502463A (hr) |
PL (1) | PL192029B1 (hr) |
RU (1) | RU2218919C2 (hr) |
TR (1) | TR200000405T2 (hr) |
WO (1) | WO1999008678A1 (hr) |
YU (1) | YU6100A (hr) |
ZA (1) | ZA987145B (hr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1257894C (zh) | 2000-12-04 | 2006-05-31 | 弗·哈夫曼-拉罗切有限公司 | 作为谷氨酸受体拮抗剂的苯基乙烯基或苯基乙炔基衍生物 |
CA2449828A1 (en) * | 2001-06-04 | 2003-01-16 | The General Hospital Corporation | Detection and therapy of vulnerable plaque with photodynamic compounds |
DE10205057A1 (de) * | 2002-02-07 | 2003-08-14 | Bayer Cropscience Ag | Substituierte 4-Hetaryl-pyrazoline |
JP4610480B2 (ja) | 2003-03-07 | 2011-01-12 | アステラス製薬株式会社 | 2,6−ジ置換スチリルを有する含窒素ヘテロ環誘導体 |
TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
BRPI0511678A (pt) | 2004-06-01 | 2008-01-08 | Hoffmann La Roche | piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5 |
ITVA20050050A1 (it) * | 2005-08-05 | 2007-02-06 | Lamberti Spa | Sistemi fotopolimerizzabili contenenti coiniziatori fotoreticolabili a bassa estraibilita' e volatilita' |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
CA2670116C (en) | 2006-11-22 | 2015-03-10 | Seaside Therapeutics, Llc | Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
AU2007336369B2 (en) | 2006-12-21 | 2013-01-17 | F. Hoffmann-La Roche Ag | Polymorphs of a mGluR5 receptor antagonist |
TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200922566A (en) | 2007-09-14 | 2009-06-01 | Ortho Mcneil Janssen Pharm | 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
MY152078A (en) | 2007-09-14 | 2014-08-15 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
AU2008297877C1 (en) * | 2007-09-14 | 2013-11-07 | Addex Pharma S.A. | 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones |
CA2704436C (en) * | 2007-11-14 | 2016-01-05 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US8691849B2 (en) | 2008-09-02 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
JP5656848B2 (ja) | 2008-10-16 | 2015-01-21 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体 |
RU2512283C2 (ru) | 2008-11-28 | 2014-04-10 | Янссен Фармасьютикалз, Инк. | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов |
PT2430022E (pt) | 2009-05-12 | 2013-12-26 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina e a sua utilização para o tratamento ou prevenção de doenças neurológicas e psiquiátricas |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
EA020671B1 (ru) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалз, Инк. | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 |
WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
CN102506473B (zh) * | 2011-10-18 | 2014-06-11 | 江苏七彩科技有限公司 | 直接蒸发式冰蓄冷制冷系统及其制冷方法 |
CN102690240B (zh) * | 2012-06-07 | 2014-09-10 | 郑州大学 | 三氮唑烯醚类、肟醚类化合物及其制备方法与应用 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
WO2015110435A1 (en) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
CN106279038A (zh) * | 2016-08-16 | 2017-01-04 | 湖南中威制药有限公司 | 一种硝酸奥昔康唑原料药的合成方法 |
KR102635938B1 (ko) | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
KR102635936B1 (ko) | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
KR20230066244A (ko) | 2021-11-06 | 2023-05-15 | 김경민 | 점선식 포장지 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4330545A (en) | 1977-02-21 | 1982-05-18 | Siegfried Aktiengesellschaft | Heterocyclic imidazolyl vinyl ethers and use of same as fungicides or bactericides |
DE2839388A1 (de) * | 1978-09-11 | 1980-03-27 | Siegfried Ag | Imidazolylvinylaether und deren verwendung |
CH648552A5 (de) * | 1981-01-23 | 1985-03-29 | Siegfried Ag | Verfahren zur herstellung von imidazolylvinylethern. |
EP0079856A1 (de) * | 1981-11-12 | 1983-05-25 | Ciba-Geigy Ag | Mikrobizide Triazolyl-vinyläther |
DE3417468A1 (de) * | 1984-05-11 | 1985-11-14 | Bayer Ag, 5090 Leverkusen | Azolylvinylether |
US5658943A (en) * | 1995-01-05 | 1997-08-19 | Warner-Lambert Company | Phenylalanine derivatives as endothelin antagonists |
-
1998
- 1998-08-06 RU RU2000106044/14A patent/RU2218919C2/ru not_active IP Right Cessation
- 1998-08-06 DE DE69822638T patent/DE69822638T2/de not_active Expired - Fee Related
- 1998-08-06 WO PCT/EP1998/004890 patent/WO1999008678A1/en not_active Application Discontinuation
- 1998-08-06 ES ES98943851T patent/ES2216305T3/es not_active Expired - Lifetime
- 1998-08-06 JP JP2000509418A patent/JP3593031B2/ja not_active Expired - Fee Related
- 1998-08-06 AT AT98943851T patent/ATE262331T1/de not_active IP Right Cessation
- 1998-08-06 EP EP98943851A patent/EP1003505B1/en not_active Expired - Lifetime
- 1998-08-06 PL PL338637A patent/PL192029B1/pl unknown
- 1998-08-06 AU AU91593/98A patent/AU741532B2/en not_active Ceased
- 1998-08-06 CN CNB988079917A patent/CN1154489C/zh not_active Expired - Fee Related
- 1998-08-06 ID IDW20000212A patent/ID28529A/id unknown
- 1998-08-06 NZ NZ502463A patent/NZ502463A/en unknown
- 1998-08-06 YU YU6100A patent/YU6100A/sh unknown
- 1998-08-06 HU HU0004412A patent/HUP0004412A3/hu unknown
- 1998-08-06 TR TR2000/00405T patent/TR200000405T2/xx unknown
- 1998-08-06 IL IL13416898A patent/IL134168A0/xx unknown
- 1998-08-06 KR KR1020007001480A patent/KR100357650B1/ko not_active IP Right Cessation
- 1998-08-06 CA CA002297732A patent/CA2297732C/en not_active Expired - Fee Related
- 1998-08-06 BR BR9811933-8A patent/BR9811933A/pt not_active Application Discontinuation
- 1998-08-07 ZA ZA987145A patent/ZA987145B/xx unknown
- 1998-08-12 AR ARP980103977A patent/AR016604A1/es not_active Application Discontinuation
-
1999
- 1999-05-04 US US09/304,624 patent/US6054588A/en not_active Expired - Fee Related
- 1999-05-04 US US09/304,909 patent/US6248901B1/en not_active Expired - Fee Related
-
2000
- 2000-02-11 HR HR20000079A patent/HRP20000079A2/hr not_active Application Discontinuation
- 2000-02-14 NO NO20000738A patent/NO20000738L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20000738L (no) | 2000-04-11 |
NZ502463A (en) | 2002-05-31 |
HUP0004412A2 (hu) | 2001-07-30 |
TR200000405T2 (tr) | 2000-08-21 |
CN1154489C (zh) | 2004-06-23 |
CA2297732C (en) | 2008-04-29 |
WO1999008678A1 (en) | 1999-02-25 |
YU6100A (sh) | 2002-10-18 |
US6054588A (en) | 2000-04-25 |
JP2001515037A (ja) | 2001-09-18 |
AU9159398A (en) | 1999-03-08 |
AR016604A1 (es) | 2001-07-25 |
KR100357650B1 (ko) | 2002-10-25 |
JP3593031B2 (ja) | 2004-11-24 |
PL338637A1 (en) | 2000-11-06 |
NO20000738D0 (no) | 2000-02-14 |
ID28529A (id) | 2001-05-31 |
EP1003505A1 (en) | 2000-05-31 |
HUP0004412A3 (en) | 2003-06-30 |
DE69822638T2 (de) | 2005-02-24 |
AU741532B2 (en) | 2001-12-06 |
BR9811933A (pt) | 2000-09-05 |
PL192029B1 (pl) | 2006-08-31 |
CA2297732A1 (en) | 1999-02-25 |
ZA987145B (en) | 1999-02-15 |
ATE262331T1 (de) | 2004-04-15 |
KR20010022877A (ko) | 2001-03-26 |
ES2216305T3 (es) | 2004-10-16 |
EP1003505B1 (en) | 2004-03-24 |
CN1266368A (zh) | 2000-09-13 |
IL134168A0 (en) | 2001-04-30 |
US6248901B1 (en) | 2001-06-19 |
DE69822638D1 (de) | 2004-04-29 |
RU2218919C2 (ru) | 2003-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20000079A2 (en) | Heterocyclic vinylethers against neurological disorders | |
US6706707B2 (en) | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | |
AU2002229567A1 (en) | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists | |
JP4177435B2 (ja) | 治療薬 | |
PT1438296E (pt) | Derivados de 1h-imidazol possuindo actividade agonística cb1, antagonista parcial cb1 ou antagonista cb1 | |
MXPA02006872A (es) | Nuevos derivados de imidazol. | |
MXPA00001528A (en) | Heterocyclic vinylethers against neurological disorders | |
RU2126403C1 (ru) | Производные фенилимидазолидинона и фармацевтическая композиция на их основе | |
HUT61730A (en) | Process for producing 2-(imidazol-1-yl)-2-benzylethylidene aminoxy alkanecarboxylic acid derivatives and pharmaceutical compositions comprising same | |
CZ2000460A3 (cs) | Heterocyklické vinylethery proti neurologickým chorobám | |
HU195655B (en) | Process for producing 8-beta-ergolinyl-methyl derivatives and pharmaceutical compositions containing them | |
CZ48094A3 (cs) | Pyrazolové deriváty, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
OBST | Application withdrawn |